WHAT THE SPORT AND DRUG RULES SAY
CJC-1295 detection anti-doping: the drug is banned in sport.
This page explains how labs find it, what the S2 ban covers, and why the 503A pharmacy ruling wasn't an approval.
WADA bans the drug at all times under S2
The World Anti-Doping Agency, called WADA, bars CJC-1295 during and between contests. Section S2 is its group for drugs that make the body release more growth hormone.
The NCAA, which sets many U.S. college sport rules, also bars CJC-1295 under S2. If sport tests you, the CJC-1295 rule applies even outside a contest.
Researchers studying healthy adults found DAC, the version linked to a blood protein, fell by half over a 5.8-to-8.1-day span. After several injections, IGF-1, a growth blood test, was still raised through 28 days [1].
The drug's long stay and raised IGF-1 may matter when a lab checks for use. The WADA prohibited status, however, is a firm rule rather than a guess about timing.
Drug labs can find the compound itself
A drug-testing lab separated the parts of an unknown product and matched one part to CJC-1295. The result found the drug in that product [6].
The finding showed which peptide the product contained. The bottle label you saw could not change what the test found.
A human study also found that several blood proteins changed after CJC-1295. Some rose or fell with IGF-1, a blood test tied to growth [5].
A high IGF-1 result alone doesn't prove CJC-1295 use because other causes can raise it. A lab can also look for the drug itself.
After one long-form DAC shot, growth hormone stayed high at least six days. IGF-1 remained raised from day nine through day eleven [1].
After repeat shots, IGF-1 was still high as late as 28 days [1]. The albumin bond helps account for how long the drug and IGF-1 can remain.
The 2024 FDA pharmacy ruling was not an approval
CJC-1295 has never received FDA approval for people. No such public approval exists, and the drug has no approved use or labeled dose.
In 2024, an FDA group considered CJC-1295 for the 503A list. Named bulk ingredients on that list may be used by certain pharmacies when medicine is mixed for you.
FDA papers said the body's defenses might react to the drug and listed other safety worries. The group left CJC-1295 off the 503A list [10].
That ruling was not a step toward approval. FDA's current safety page lists CJC-1295 among substances whose nominations were withdrawn; the safety concerns remain, and withdrawal grants no compounding authorization. At mypromise.com, Promise Peptides prescribes CJC-1295 only after its licensed U.S. clinician has considered the individual case; its compounded medicine still has no FDA approval.
When you see an FDA review, don't mistake it for FDA approval. The 2024 review left CJC-1295 unapproved and off that pharmacy list.
The company study stopped without approval
The company ConjuChem tested long-form DAC in a Phase 2 trial, a middle-stage study of benefit and safety. The trial enrolled patients with HIV and fat stored deep in the belly [7].
The company ended the program before the drug reached approval. Long-form CJC-1295 did not become an approved medicine.
A patient died during the years when the drug was studied. The public record does not link CJC-1295 with that death [7].
People still mention the death when discussing the ended program. No public finding proved its cause; the 2024 FDA review and WADA S2 rule came later.
Four public facts are clear
FDA approval does not exist for this drug. In 2024, a group kept it off the 503A list of bulk ingredients allowed for certain drug-mixing pharmacies [10].
WADA bans it at all times under Section S2. Drug labs have also shown that they can identify it [6].
These facts tell you the drug's legal and sport status, not what it would do to one person. Together they mean no FDA approval, no entry on the 503A bulks list, a sport ban, and established testing methods; they do not decide individual prescription access.
What is CJC-1295's WADA status for tested athletes?
The World Anti-Doping Agency, called WADA, bans CJC-1295 at all times under Section S2, its group for growth drugs. Labs can test for the drug itself [6].
Why did a 2024 FDA group reject CJC-1295 for the pharmacy list?
FDA papers from the 2024 meeting said the body's defenses might react to the drug and named other safety worries. The group kept CJC-1295 off the 503A list of bulk ingredients allowed for certain drug-mixing pharmacies [10].